CDC37 and Miyoshi myopathy: As shown in Figure S3, bortezomib treatment for 8 hours at increasing concentrations (1, 5 or 10 nM) did not affect the high levels of Cdc37 Ser13 phosphorylation already present in MM cells; however, it caused a dose-dependent increase of NF-κB p65 Ser529 phosphorylation in all the three MM cell lines tested.